Seqens Seqens

X

Find the latest Drugs in Development and Pipeline Prospector News of Foundation for Angelman Syndrome Therapeutics.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Foundation for Angelman Syndrome Therapeutics
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
PO Box 608 Downers Grove, IL 60515
Telephone
Telephone
(866) 783-0078

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Collaboration will support the preclinical studies of the potential benefit of Lixte’s proprietary lead clinical compound, LB-100, in a mouse model of Angelman Syndrome (AS).


Lead Product(s): LB-100

Therapeutic Area: Genetic Disease Product Name: LB-100

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Lixte Biotechnology

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration August 18, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY